YHP 2205
Alternative Names: YHP-2205Latest Information Update: 21 Jan 2025
Price :
$50 *
At a glance
- Originator Yuhan
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 15 Jan 2025 Phase-I clinical trials in Unspecified (In volunteers) in South Korea (PO) (NCT06775522)
- 17 Apr 2024 Preclinical trials in Unspecified in South Korea (PO) (NCT06359626)
- 11 Apr 2024 Yuhan Corporation plans phase-I bioequivalence trial (In volunteers) in July 2024 (PO) (NCT06359626)